The increase in the price target from $35 to $43 suggests that JP Morgan sees potential for Genpact's stock to appreciate, despite maintaining a Neutral rating. This could lead to a positive short-term impact on the stock price as investors may interpret the higher price target as a sign of confidence in the company's future performance.